BeiGene (BGNE) Issues Positive Update on BGB-3111 as Waldenström’s Macroglobulinemia Treatment
Tweet Send to a Friend
BeiGene, Ltd. (Nasdaq: BGNE) presented updated clinical data from an ongoing Phase I study of BTK inhibitor BGB-3111 in patients ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
